Contact Us marketing@medicilon.com
ABOUT
Company Profile
Corporate Culture
Management Team
Company History
Message from the CEO
Honors and Awards
SERVICES
SERVICES
01 Drug Discovery
Chemistry Research Biology Research Early Pharmacokinetics
02 Pharmaceutical Research
Intermediates Active Pharmaceutical Ingredients Pharmaceutical preparation Analytical Method Development and Quality Control CMC Filings Analytical Testing Center
03 Preclinical Research
Pharmacology & Pharmacodynamics Drug Safety Evaluation DMPK Bioanalysis IND Filings
PLATFORM
PLATFORM
01 One-stop Integrated Services
Liposome Drug Development Drug Discovery Pharmaceutical Research Preclinical Research Botanical Drug Preclinical R&D
02 Innovative Drug R&D Services
Peptide Drug Conjugate (PDC) Antibody Nucleic Acid Drug Cellular Immunotherapies mRNA Vaccine PROTAC ADC
03 Key Technical Services for Drug R&D
Cytokine and Biomarker Detection Metabolite Identification (MetID) Drug Forming Research Flow Cytometry Technology SEND Format Conversion Flow Sorting NanoString nCounter Detection Routes of Drug Administration
04 Drug Efficacy Evaluation for Common Diseases
Rodent Cerebrovascular Disease Inflammatory and Immune Diseases IO Pharmacodynamic Model
05 High-end Preparations Technology Platform
Skin Topical Preparation Ophthalmic drug Inhalation drug
06 Targeted Drugs R&D Services
STAT3-targeted Drugs R&D Service KRAS-targeted Drugs R&D Service GLP-1 New Drug R&D Service
07 Safety Assessment Lab of Process Chemistry

08 Public Services
CAREERS
Talent Development
Campus Recruitment
Recruitment
NEWS
Medicilon Events
Featured Stories
Market Events
Videos
A.C.E.
INVESTORS
Stock Information
Investment Contact
CLIENT CENTER
Intellectual Property Protection
Clients Testimonials
Downloads
Partnerships
Medicilon Support
Newsletters
CN
×
中
Close Button
Customer Center
Customer Center
Case Studies Clients Testimonials Downloads Partnerships Intellectual Property Protection Newsletters
HomeClient CenterMedicilon SupportIND 100
IND 100 Publications
Jun 11,2024
Medicilon helps Sungening Biological's first innovative drug SG1001 oral tablet obtain IND approval in China
Recently, Sungening Biological's (Sungening) first innovative drug SG1001 successfully obtained the implicit clinical trial approval from the National Medical Products Administration (Acceptance Number: CXHL2400203).
See More
Medicilon helps Sungening Biological's first innovative drug SG1001 oral tablet obtain IND approval in China
Jun 11,2024
Medicilon assists the world's first, Leado Pharma's IBD treatment FIC new drug IND application approved by the US FDA
On May 11, Leado Pharma (Leado) announced that the company's independently developed First-in-class new drug LD09163 tablets for treating inflammatory bowel disease has obtained IND approval from the US FDA and officially entered the clinical development stage.
See More
Medicilon assists the world's first, Leado Pharma's IBD treatment FIC new drug IND application approved by the US FDA
Jun 11,2024
Medicilon congratulates - Treatable and Accessible! Adult and adolescent Type A and Type B influenza! AnDiCon Bio's pill cures influenza with the new drug Madoxanavir - Phase III successful research
Medicilon, as a partner of AnDiCon, provided formulation research services for the 'pediatric version' of the anti-influenza Class 1 Madoxanavir granules for influenza, assisting in its rapid advancement in preclinical research and development processes.
See More
Medicilon congratulates - Treatable and Accessible! Adult and adolescent Type A and Type B influenza! AnDiCon Bio's pill cures influenza with the new drug Madoxanavir - Phase III successful research
Mar 19,2024
Medicilon assists Biotime obtain approval for its first dual-filing innovative drug in China and the United States
Shanghai Medicilon Inc. (Medicilon) provides one-stop preclinical R&D services from target to IND application for the research and development of BIOT-001, and fully empowers BIOT-001 tablets to obtain the approval in China and United States.
See More
Medicilon assists Biotime obtain approval for its first dual-filing innovative drug in China and the United States
Mar 11,2024
Medicilon assists Shanghai Institute of Biological Products' innovative ADC drug obtain clinical approval
On February 19, SIBP-A17, the second class I innovative antibody drug conjugate (ADC) independently developed by China National Pharmaceutical Group's Shanghai Institute of Biological Products, received a clinical trial approval notice from the National Medical Products Administration (NMPA).
See More
Medicilon assists Shanghai Institute of Biological Products' innovative ADC drug obtain clinical approval
Feb 28,2024
Medicilon assists Shijiazhuang No.4 Pharmaceutical's Class 1 new chemical drug SYN045 tablets obtain clinical approval
​On January 26, SYN045, a Class I new drug developed by Shijiazhuang No.4 Pharmaceutical, received a clinical trial approval notice from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA).
See More
Medicilon assists Shijiazhuang No.4 Pharmaceutical's Class 1 new chemical drug SYN045 tablets obtain clinical approval
Jan 22,2024
Medicilon Assists Hebei Changshan Biochemical Pharmaceutical Co obtain approval for clinical research on Class 1 new drug CSCJC3456 tablets
Changshan Kaijiejian Biopharmaceutical Research and Development (Hebei) Co., Ltd. recently received the approval of the National Medical Products Administration (NMPA) to issue a "Drug Clinical Trial Approval Notice" for the new Class 1 chemical drug CSCJC3456 tablets. Medicilon has efficiently completed most of the preclinical research work of CSCJC3456, including drug efficacy, pharmacokinetics and safety evaluation promoting the project to quickly complete the preclinical research and development process.
See More
Medicilon Assists Hebei Changshan Biochemical Pharmaceutical Co obtain approval for clinical research on Class 1 new drug CSCJC3456 tablets
Dec 12,2023
Medicilon Assists Zhigen Pharmaceutical's new antidepressant drug ZG-001 to get approval for clinical trials
ZG-001 developed by Zhigen Pharmaceutical has received the "Drug Clinical Trial Approval Notice" approved and issued by NMPA. Medicilon provided ZG-001 with one-stop R&D services such as pharmaceutical research, preclinical research, and IND filing application.
See More
Medicilon Assists Zhigen Pharmaceutical's new antidepressant drug ZG-001 to get approval for clinical trials
Dec 08,2023
Medicilon Assists Longsee Biomedical's live bacteria preparation LF01 capsules approved for clinical use
On November 20, LF01, an innovative anti-tumor drug independently developed by Longsee Biomedical Co. Ltd. (Longsee Biomedical), received the NMPA drug clinical trial approval notice. Medicilon provided non-clinical safety evaluation and filing application services for the research and development of LF01.
See More
Medicilon Assists Longsee Biomedical's live bacteria preparation LF01 capsules approved for clinical use
Dec 08,2023
Medicilon Assists Yuyao Biotech's STAT3 dual phosphorylation site inhibitor YY201 successfully completed dual submissions in China and US
Medicilon provided YY201 with pharmaceutical research services (including APIs and preparations), preclinical research services (including efficacy, pharmacokinetics, safety evaluation), and IND application services, which helped YY201 successfully complete dual submissions in China and US.
See More
Medicilon Assists Yuyao Biotech's STAT3 dual phosphorylation site inhibitor YY201 successfully completed dual submissions in China and US
Stock Code
688202

Global

Address: 20 Maguire Road, Suite 103, Lexington, MA 02421(America)

Tel: +1(781)535-1428(U.S.)

Address: Allia Future Business Centre Kings Hedges Road Cambridge CB4 2HY, UK

Tel: 0044 7790 816 954 (Europe)

Email: marketing@medicilon.com

  

Address: 5th Floor, 62, Banpodae-ro 4-gil, Seocho-gu, Seoul, 06719 South Korea

Tel: +82 70-8269-5849

China

Address: No.585 Chuanda Road, Pudong New Area, Shanghai (Headquarters)

Postcode: 201299

Tel: +86 (21) 5859-1500 (main line)

Fax: +86 (21) 5859-6369

Facebook icon
Twitter icon
Linkedin icon
Youtube icon
© 2023 Shanghai Medicilon Inc. All rights reserved All Rights Reserved Privacy Policy
Website Map
-->